Taro Pharmaceutical Industries Ltd. (NYSE:TARO) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Friday.

Other equities research analysts have also recently issued reports about the stock. TheStreet cut shares of Taro Pharmaceutical Industries from a “b-” rating to a “c+” rating in a research report on Wednesday. Credit Suisse Group cut shares of Taro Pharmaceutical Industries from an “outperform” rating to a “neutral” rating in a research report on Tuesday, May 23rd.

Shares of Taro Pharmaceutical Industries (TARO) traded up 1.01% during mid-day trading on Friday, hitting $98.24. The company had a trading volume of 44,694 shares. The firm’s 50-day moving average price is $113.86 and its 200 day moving average price is $112.80. Taro Pharmaceutical Industries has a one year low of $92.28 and a one year high of $137.98. The company has a market capitalization of $3.98 billion, a P/E ratio of 10.00 and a beta of 0.64.

Taro Pharmaceutical Industries (NYSE:TARO) last posted its quarterly earnings data on Monday, May 22nd. The company reported $2.05 EPS for the quarter. The business had revenue of $196.41 million for the quarter. Taro Pharmaceutical Industries had a net margin of 49.69% and a return on equity of 20.08%. Analysts predict that Taro Pharmaceutical Industries will post $9.49 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Taro Pharmaceutical Industries Ltd. (NYSE:TARO) Stock Rating Lowered by BidaskClub” was first published by Watch List News and is owned by of Watch List News. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at https://www.watchlistnews.com/taro-pharmaceutical-industries-ltd-nysetaro-stock-rating-lowered-by-bidaskclub/1472294.html.

A number of large investors have recently bought and sold shares of TARO. Anchor Capital Advisors LLC boosted its stake in Taro Pharmaceutical Industries by 0.4% in the second quarter. Anchor Capital Advisors LLC now owns 20,733 shares of the company’s stock valued at $2,323,000 after buying an additional 77 shares in the last quarter. Bank of Montreal Can boosted its stake in Taro Pharmaceutical Industries by 7.5% in the second quarter. Bank of Montreal Can now owns 2,128 shares of the company’s stock valued at $238,000 after buying an additional 149 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in Taro Pharmaceutical Industries by 7.4% in the second quarter. Russell Investments Group Ltd. now owns 2,257 shares of the company’s stock valued at $253,000 after buying an additional 156 shares in the last quarter. Wells Fargo & Company MN boosted its stake in Taro Pharmaceutical Industries by 11.2% in the second quarter. Wells Fargo & Company MN now owns 1,685 shares of the company’s stock valued at $189,000 after buying an additional 170 shares in the last quarter. Finally, Creative Planning boosted its stake in Taro Pharmaceutical Industries by 3.8% in the second quarter. Creative Planning now owns 7,186 shares of the company’s stock valued at $805,000 after buying an additional 265 shares in the last quarter. 16.41% of the stock is currently owned by institutional investors and hedge funds.

Taro Pharmaceutical Industries Company Profile

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.

Receive News & Ratings for Taro Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.